<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01523847</url>
  </required_header>
  <id_info>
    <org_study_id>IIL - HD0803</org_study_id>
    <secondary_id>EudraCT Number 2009-013839-37</secondary_id>
    <nct_id>NCT01523847</nct_id>
  </id_info>
  <brief_title>A Multi-centre Study of MBVD in Elderly and/or Cardiopathic Patients Affected by Hodgkin's Lymphoma (HL)</brief_title>
  <acronym>HD0803</acronym>
  <official_title>A Phase II Multi-centre Study of MBVD in Elderly and/or Cardiopathic Patients Affected by Hodgkin's Lymphoma (HL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione Italiana Linfomi ONLUS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fondazione Italiana Linfomi ONLUS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study has the purpose to evaluate in elderly and/or cardiopathic HL patients, the&#xD;
      cardiologic toxicity of the MBVD regimen, where liposomal doxorubicin (Myocet®) is&#xD;
      substituted for doxorubicin in the conventional ABVD regimen.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      STUDY POPULATION Patients affected by Hodgkin's lymphoma, any stage, older than 69 years.&#xD;
      Patients affected by Hodgkin's Lymphoma with concomitant cardiopaty, older than 18 years.&#xD;
&#xD;
      AIMS OF THE STUDY&#xD;
&#xD;
        -  To evaluate in elderly and/or cardiopathic HL patients, the cardiologic toxicity of the&#xD;
           MBVD regimen, where liposomal doxorubicin (Myocet®) is substituted for doxorubicin in&#xD;
           the conventional ABVD regimen&#xD;
&#xD;
        -  To compare in a pair-match retrospective analysis the results obtained with MBVD with&#xD;
           those obtained in patients comparable for clinical variables and treated with ABVD or&#xD;
           with the reduced intensity VEPEMB schedule.&#xD;
&#xD;
      STUDY DESIGN Multi-centre phase II study SAMPLE SIZE 50 patients&#xD;
&#xD;
      STUDY PROCEDURES&#xD;
&#xD;
        -  Histologic diagnosis of Hodgkin Lymphoma.&#xD;
&#xD;
        -  Early Staging evaluation including:&#xD;
&#xD;
             -  Blood tests&#xD;
&#xD;
             -  CT, PET and bone marrow biopsy.&#xD;
&#xD;
             -  Heart and lung function evaluation.&#xD;
&#xD;
             -  Geriatric assessment.&#xD;
&#xD;
             -  Quality of life evaluation.&#xD;
&#xD;
        -  2 MBVD courses&#xD;
&#xD;
        -  Early restaging with PET scan (PET-2)&#xD;
&#xD;
        -  The subsequent treatment will be planned as follows:&#xD;
&#xD;
             -  Stage I and IIA patients will go on with 1 more course of MBVD (total of 3 courses)&#xD;
                followed by involved field radiotherapy (30 Gy-36Gy).&#xD;
&#xD;
             -  Advanced stage (IIB-IV) patients will go on with 4 more courses of MBVD (total of 6&#xD;
                courses). Radiotherapy limited to bulky or non complete responder areas (30-36 Gy)&#xD;
                is optional.&#xD;
&#xD;
        -  Final restaging including:&#xD;
&#xD;
             -  Blood tests&#xD;
&#xD;
             -  CT, PET&#xD;
&#xD;
             -  bone marrow biopsy if positive at baseline.&#xD;
&#xD;
             -  Heart and lung function evaluation.&#xD;
&#xD;
             -  Geriatric assessment.&#xD;
&#xD;
             -  Quality of life evaluation&#xD;
&#xD;
      Follow up procedures will include:&#xD;
&#xD;
        1. a clinical and laboratory evaluation (with troponin, proBNP / BNP, cardiology visit, ECG&#xD;
           and echocardiogram) every 6 months in the first 2 years, then annually.&#xD;
&#xD;
        2. CT scans will be planned annually.&#xD;
&#xD;
        3. Compilation of geriatric evaluation scales every 6 months in the first 2 years, then&#xD;
           annually.&#xD;
&#xD;
      MBVD will be scheduled as follows (4 weeks):&#xD;
&#xD;
      Myocet 25 mg/mq i.v. day 1 and 15 Bleomycin 10 mg/mq i.v. day 1 and 15 Vinblastine 6 mg/mq&#xD;
      i.v. day 1 and 15 Dacarbazine 375 mg/mq i.v. day 1 and 15 Supportive treatment with G-CSF&#xD;
      and/or Erythropoietin will be planned according to international guide-lines.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Response (CR) at the end of the chemotherapy program</measure>
    <time_frame>24 weeks</time_frame>
    <description>CR is defined according to the Cheson 2007 response criteria.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiac Toxicity during the chemotherapy program measured by CTCAE v.3</measure>
    <time_frame>24 weeks</time_frame>
    <description>Evaluation of Cardiac Toxicity during the chemotherapy program measured by CTCAE v.3</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiac toxicity of MBVD after two courses of MBVD measured by CTCAE v.3</measure>
    <time_frame>8 weeks</time_frame>
    <description>Evaluation of cardiac toxicity of MBVD in elderly and/or cardiopathic patients with Hodgkin's lymphoma after two courses of MBVD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>24 months</time_frame>
    <description>PFS will be measured from the day of enrolment to the date of disease progression, relapse or death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse Free Survival (RFS) of patients entering complete remission</measure>
    <time_frame>24 months</time_frame>
    <description>RFS is defined only for patients who achieve CR, and is measured from the date of attaining the disease-free state until the date of relapse or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>24 months</time_frame>
    <description>OS will be measured from the day of enrolment to the date of relapse or death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from the theoretical total amount of drug delivered in a one-week period (dose-intensity)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Proportion of dose-intensity delivered to patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cardiac markers during and at the end of chemotherapy</measure>
    <time_frame>24 weeks</time_frame>
    <description>Evaluate Change in cardiac markers during and at the end of chemotherapy</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>MBVD (Myocet+BVD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 MBVD courses, after early restaging with PET scan (PET-2)&#xD;
The subsequent treatment will be planned as follows:&#xD;
-Stage I and IIA patients will go on with 1 more course of MBVD (total of 3 courses) followed by involved field radiotherapy (30 Gy-36 Gy).&#xD;
-Advanced stage (IIB-IV) patients will go on with 4 more courses of MBVD (total of 6 courses). Radiotherapy limited to bulky or non complete responder areas (30 Gy) is optional.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MBVD (Myocet+BVD)</intervention_name>
    <description>MBVD will be scheduled as follows:&#xD;
Myocet 25 mg/mq i.v. day 1 and 15 Bleomycin 10 mg/mq i.v. day 1 and 15 Vinblastine 6 mg/mq i.v. day 1 and 15 Dacarbazine 375 mg/mq i.v. day 1 and 15</description>
    <arm_group_label>MBVD (Myocet+BVD)</arm_group_label>
    <other_name>MBVD</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed Hodgkin's lymphoma, except for nodular lymphocyte&#xD;
             predominance subgroup.&#xD;
&#xD;
          -  Previously untreated&#xD;
&#xD;
          -  Age ≥ 70.&#xD;
&#xD;
          -  Age&gt; 18 in presence of cardiopathy according to inclusion criteria…&#xD;
&#xD;
          -  Patients with HCV and HBV infection can be included. For patients HBV+ occult carriers&#xD;
             (AntiHBc+, HbsAg-, AntiHBs+/-) Lamivudine prophylaxis is mandatory.&#xD;
&#xD;
          -  Life expectancy &gt;3 months&#xD;
&#xD;
          -  Informed consent.&#xD;
&#xD;
          -  Staging with PET-CT.&#xD;
&#xD;
          -  Preliminary geriatric assessment (ADL, IADL, co-morbidity and frailness scores).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Lymphocyte predominance subgroup&#xD;
&#xD;
          -  Age &lt; 70 (no cardiopathy)&#xD;
&#xD;
          -  Age &lt; 18 (with cardiopathy).&#xD;
&#xD;
          -  HIV infection.&#xD;
&#xD;
          -  Previous treatments for Hodgkin's lymphoma.&#xD;
&#xD;
          -  Other concomitant or previous malignancies, with the exception of basal cell skin&#xD;
             tumors, adequately treated carcinoma in situ of the cervix and any cancer that has&#xD;
             been in complete remission for &gt; 5 years.&#xD;
&#xD;
          -  Renal failure (creatinine higher than twice the normal level) or liver disease&#xD;
             (AST/ALT or bilirubin level higher than 2.5 times the normal level)&#xD;
&#xD;
          -  Other clinical situations that contraindicate, to the judgment of investigators, the&#xD;
             administration of a mild-dose chemotherapy. Isolated comorbidities will be scored and&#xD;
             recorded, but they are not, if isolated, a sufficient reason for exclusion.&#xD;
&#xD;
          -  Frail patients, defined according to comorbidity scale: patients with 1 grade 4&#xD;
             comorbidity, or &gt;3 grade 3 comorbidities, are excluded. (see appendix.6)&#xD;
&#xD;
          -  Unresponsive sepsis&#xD;
&#xD;
          -  Dementia&#xD;
&#xD;
          -  Impossibility to subscribe the informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alessandro Levis, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Azienda Ospedaliera SS Antonio, Biagio e Cesare Arrigo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ospedale Cardinale Giovanni Panico</name>
      <address>
        <city>Tricase</city>
        <state>Lecce</state>
        <zip>73039</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.S.U.R. Zona Territoriale n°8 - Ospedale di Civitanova Marche U.O. Medicina Interna ed Ematologia</name>
      <address>
        <city>Civitanova Marche</city>
        <state>Macerata</state>
        <zip>62012</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SC Medicina trasfusionale ed Ematologia Ospedale civile di Ivrea</name>
      <address>
        <city>Ivrea</city>
        <state>Torino</state>
        <zip>10015</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera SS. Antonio e Biagio e C. Arrigo</name>
      <address>
        <city>Alessandria</city>
        <zip>15121</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro di riferimento Oncologico</name>
      <address>
        <city>Aviano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCC Istituto Tumori</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico S. Orsola Malpighi</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spedali Civili</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale &quot;A. Perrino&quot;</name>
      <address>
        <city>Brindisi</city>
        <zip>72100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Businco</name>
      <address>
        <city>Cagliari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia Ospedale Vito Fazzi</name>
      <address>
        <city>Lecce</city>
        <zip>73100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Area Vasta Romagna e IRST</name>
      <address>
        <city>Meldola (FC)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Maggiore della Carità</name>
      <address>
        <city>Novara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera V.Cervello</name>
      <address>
        <city>Palermo</city>
        <zip>90146</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Guglielmo da Saliceto</name>
      <address>
        <city>Piacenza</city>
        <zip>29100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osp. S. Maria delle Croci</name>
      <address>
        <city>Ravenna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera &quot;Bianchi Melacrino Morelli&quot;</name>
      <address>
        <city>Reggio Calabria</city>
        <zip>89124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia Azienda Ospedaliera Arcispedale &quot;S. Maria Nuova&quot;</name>
      <address>
        <city>Reggio Emilia</city>
        <zip>42100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Oncologia Ospedale civile degli Infermi</name>
      <address>
        <city>Rimini</city>
        <zip>47900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O.C. Ematologia IRCCS Istituti Fisioterapici Ospitalieri</name>
      <address>
        <city>Roma</city>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Eugenio</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università &quot;La Sapienza&quot;</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Santa Maria</name>
      <address>
        <city>Terni</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Struttura Complessa di Ematologia PO TREVISO</name>
      <address>
        <city>Treviso</city>
        <zip>31100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero - Universitaria di Udine</name>
      <address>
        <city>Udine</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>June 22, 2011</study_first_submitted>
  <study_first_submitted_qc>January 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2012</study_first_posted>
  <last_update_submitted>August 3, 2016</last_update_submitted>
  <last_update_submitted_qc>August 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hodgkin Lymphoma</keyword>
  <keyword>Cardiopathic</keyword>
  <keyword>elderly</keyword>
  <keyword>Myocet</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>July 10, 2018</submitted>
    <returned>January 22, 2019</returned>
    <submitted>November 12, 2019</submitted>
    <returned>November 29, 2019</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

